{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:14:16Z","timestamp":1781846056119,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.pnpbp.2013.09.016","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T18:24:39Z","timestamp":1380738279000},"page":"86-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine"],"prefix":"10.1016","volume":"48","author":[{"given":"Philip T.","family":"Ninan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Guico-Pabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2013.09.016_bb0005","series-title":"Diagnostic and statistical manual of mental disorders, text revision: DSM-IV-TR","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0010","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jpsychires.2010.04.015","article-title":"The cortisol awakening response in patients remitted from depression","volume":"44","author":"Aubry","year":"2010","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jad.2009.03.017","article-title":"Depression, traumatic stress and interleukin-6","volume":"120","author":"Bob","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0020","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/15622971003611319","article-title":"Serum and plasma BDNF levels in major depression: a replication study and meta-analyses","volume":"11","author":"Bocchio-Chiavetto","year":"2010","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0025","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1017\/S1461145708009309","article-title":"A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression","volume":"11","author":"Brunoni","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/dneu.20758","article-title":"The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity","volume":"70","author":"Castren","year":"2010","journal-title":"Dev Neurobiol"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0035","doi-asserted-by":"crossref","first-page":"M201","DOI":"10.1093\/gerona\/52A.4.M201","article-title":"The association of plasma IL-6 levels with functional disability in community-dwelling elderly","volume":"52","author":"Cohen","year":"1997","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000319946","article-title":"Associations between brain-derived neurotrophic factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients","volume":"62","author":"Dell'Osso","year":"2010","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0045","first-page":"54","article-title":"Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment","volume":"46","author":"Deuschle","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0055","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0b013e31822c0a68","article-title":"Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo","volume":"31","author":"Dunlop","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145709991039","article-title":"Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders?","volume":"13","author":"Gass","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jpsychires.2011.09.011","article-title":"Salivary cortisol profiles in patients remitted from recurrent depression: one-year follow-up of a mindfulness-based cognitive therapy trial","volume":"46","author":"Gex-Fabry","year":"2012","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1440-1819.2010.02113.x","article-title":"Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions","volume":"64","author":"Hashimoto","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.psyneuen.2008.10.026","article-title":"Salivary cortisol as a biomarker in stress research","volume":"34","author":"Hellhammer","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-2007-1004594","article-title":"Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment","volume":"41","author":"Hellweg","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.biopsych.2009.06.023","article-title":"Cognitive impairment in major depression: association with salivary cortisol","volume":"66","author":"Hinkelmann","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/YCT.0b013e3181c18bbf","article-title":"The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression","volume":"26","author":"Hu","year":"2010","journal-title":"J ECT"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0100","first-page":"363","article-title":"Serum brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression","volume":"23","author":"Jevtovic","year":"2011","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0110","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.psyneuen.2010.04.001","article-title":"Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis","volume":"35","author":"Knorr","year":"2010","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.psychres.2012.05.015","article-title":"The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression\u2014a randomised trial","volume":"200","author":"Knorr","year":"2012","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpsychires.2008.03.014","article-title":"Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6months treatment with sertraline, escitalopram, or venlafaxine","volume":"43","author":"Matrisciano","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0120","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/mp.2010.98","article-title":"Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment","volume":"16","author":"Molendijk","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0175","author":"R&D Systems"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0180","author":"R&D Systems"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0140","series-title":"Handbook of psychiatric measures","first-page":"113","article-title":"Sheehan disability scale","author":"Sheehan","year":"2000"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.pnpbp.2010.08.011","article-title":"The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study","volume":"35","author":"Tadic","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0150","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.pnpbp.2011.06.013","article-title":"Serum BDNF levels before treatment predict SSRI response in depression","volume":"35","author":"Wolkowitz","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0185","author":"World Health Organization"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0160","author":"World Health Organization"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00213-010-1956-y","article-title":"Nicotine dependence and serum BDNF levels in male patients with schizophrenia","volume":"212","author":"Zhang","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2013.09.016_bb0170","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.neurobiolaging.2006.06.011","article-title":"Serum neurotrophins\u2014a study on the time course and influencing factors in a large old age sample","volume":"28","author":"Ziegenhorn","year":"2007","journal-title":"Neurobiol Aging"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461300211X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461300211X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T12:53:26Z","timestamp":1539348806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858461300211X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":34,"alternative-id":["S027858461300211X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.09.016","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}